<DOC>
	<DOCNO>NCT02856789</DOCNO>
	<brief_summary>The purpose study give proof concept Fibrin structure assay STA-R® prototype . It aim identify parameter discriminate pathologic normal population . Secondary objective determine precision assay , record Fibrin activity , comparatively thromboelastography TEG® , coagulation activation assay coagulation-lysis assay .</brief_summary>
	<brief_title>Determination Fibrin Activity Plasma STA-R® Prototype</brief_title>
	<detailed_description>Background . Fibers thickness fibrin clot play important role clot stability resistance fibrinolysis . An innovative concept , base relationship light spectrum fibrin clot fiber nanostructure ( C.Dassi et al , ISTH 15ABS-3593 ) , thanks multi-wavelength STA-R® prototype , allow real time determination fibrin structure ( FS ) plasma . Preliminary result suggest new automate FS method provide new data clot analysis could useful tool clinical practice management hemostasis disorder . This study extend begin september 2017 . Main objective . This study aim determine precision , normal range FS method comparison Thromboelastography TEG® discriminate patient healthy volunteer ( HV ) . Recruitment . 50 healthy volunteer without know coagulation trouble , enrol coagulation test blood donation . 30 hospitalized patient patient consultation , without ongoing treatment ( particularly anticoagulant treatment ) , normal hemostasis screening ( Prothombin Time , Activated Partial Prothombine Time Fibrinogen Level ) . 30 hospitalized patient pathology know able induce increase decrease fibrinogen level , mainly trauma patient enrol coagulation test . The study conduct compliance French regulation ethic approval . FS Assays . The FS determination STA-R® prototype TEG® realize fresh plasma whole blood sample respectively Hôpital d'Instruction de armées Percy . The screening test ( PT , APTT , Fibrinogen ) STA-R® Evolution measurement FS second STA-R® prototype perform frozen plasma STAGO laboratory . Statistical analysis result . A statistical analysis determine relevant parameter discrimination pathologic population normal population , quality control precision . Then , statistical analysis compare STA-R® prototype method TEG® method point population discriminate method .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Hemorrhagic Disorders</mesh_term>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<criteria>Patients healthy volunteer nonopposition participate evaluation Healthy volonteers ongoing treatment Healthy volonteers abnormal hemostasis result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Fibrin structure</keyword>
	<keyword>Thromboelastography</keyword>
	<keyword>Fibrin formation</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>TEG 5000</keyword>
	<keyword>TEG 6S</keyword>
	<keyword>Coagulo-lytic balance</keyword>
	<keyword>Normal range</keyword>
</DOC>